Back to top
more

Array Technologies (ARRY)

(Real Time Quote from BATS)

$5.87 USD

5.87
2,304,945

-0.04 (-0.68%)

Updated Aug 6, 2025 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Solar

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for March 15th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

3 Solar Stocks to Watch as Clean Energy Drive Accelerates

by Zacks Equity Research

Solar energy seems poised to witness growth as the focus shifts to renewables, making it wise to look at names like Enphase Energy (ENPH), Array Technologies (ARRY) and First Solar (FSLR).

Zacks Equity Research

The Zacks Analyst Blog Highlights: SolarEdge Technologies, Array Technologies, Renesola, SunPower and NextEra Energy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: SolarEdge Technologies, Array Technologies, Renesola, SunPower and NextEra Energy

Sreoshi Bera headshot

4 Solar Stocks to Shine on Green Energy Initiatives

by Sreoshi Bera

The prospects for solar stocks are bright, which calls for investing in SolarEdge (SEDG), Array Tech (ARRY), Canadian Solar (CSIQ) and ReneSola (SOL).

Tirthankar Chakraborty headshot

5 Solid Renewable Energy Stocks to Watch for Growth Now

by Tirthankar Chakraborty

From technological progress and tax subsidies to low costs to initiatives for a greener environment, all are expected to boost renewable energy stocks like Renesola (SOL) and SunPower (SPWR).

Archan Sarkar headshot

US Solar Market Prospects Bright for 2021: 3 Stocks in Focus

by Archan Sarkar

In 2021 and beyond, factors such as declining cost of solar projects as well as ample corporate investments are expected to boost the U.S. solar market.

Zacks Equity Research

Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan

by Zacks Equity Research

Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.

Zacks Equity Research

What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

by Zacks Equity Research

Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.

Zacks Equity Research

What's in the Cards for Pfizer (PFE) This Earnings Season?

by Zacks Equity Research

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.

Zacks Equity Research

Array BioPharma (ARRY) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sweta Killa headshot

Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FNY

Zacks Equity Research

Abbvie Decides to Acquire Allergan

by Zacks Equity Research

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

by Mark Vickery

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

by Neena Mishra

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Zacks Equity Research

Eldorado to Buy Caesars

by Zacks Equity Research

Eldorado to Buy Caesars

Mark Vickery headshot

U.S. Senate Takes on Big Tech, Plus "Merger Monday"

by Mark Vickery

Eldorado Resorts (ELR) has agreed to buy Caesars (CZR) for $8.6 billion, and a bipartisan bill in the Senate holds Big Tech accountable for monetized user data.

Ekta Bagri headshot

3 Big Biotechs Hold Growth Potential in Second Half of 2019

by Ekta Bagri

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

Swarup Gupta headshot

Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

by Swarup Gupta

The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

Zacks Equity Research

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

by Zacks Equity Research

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

Kinjel Shah headshot

Big Drugmakers That May Tread the M&A Path After Pfizer

by Kinjel Shah

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

Sweta Killa headshot

Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

by Sweta Killa

Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

Zacks Equity Research

Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

by Zacks Equity Research

Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.

Zacks Equity Research

Company News For Jun 18, 2019

by Zacks Equity Research

Companies In The News Are: DISH,TMUS,S,ARRY,PFE,BID,BA

Zacks Equity Research

Big Ticket Mergers Are in Focus

by Zacks Equity Research

Big Ticket Mergers Are in Focus

Mark Vickery headshot

"Merger Monday" Returns: Pfizer Buying Array, T-Mobile-Sprint on Ice?

by Mark Vickery

News on two major mergers in their respective industries are taking headlines, along with a fresh regional economic read.